Vaccine Development Insights

10.2 billion healthy years of life Recent announcements in the United States to reduce recommended childhood vaccinations raise serious concerns. At a time of growing mistrust in science, stepping away from decades of robust evidence weakens public health systems and increases the risk of the return of vaccine-preventable diseases. This context underscores how essential it is to uphold a scientific voice that is evidence-based, independent, and fully engaged in the public debate. It was in this spirit that I had the honor of speaking yesterday as part of the William E. Paul Lecture at The National Institutes of Health. Bill Paul was a giant of immunology at the National Institute of Health , whose leadership was central to the creation of the Vaccine Research Center at the NIH. This lecture discussed new vaccine strategies and was an opportunity to reaffirm a fundamental truth: vaccines are among the safest, most effective, and most powerful public health tools ever developed. At a moment when vaccine research in the United States is being weakened, and when vaccination coverage against life-threatening diseases such as measles is declining, this message could not be more urgent. As a result of 50 years of vaccination, a child born today has a 40% increase in survival for each year of infancy and childhood. Considering the added benefit of reduced morbidity, 10.2 billion healthy years of life have been gained due to vaccination (Lancet Vol 403, 2024) We need a clear and collective reminder of how much vaccines have done for humanity and a renewed commitment to protect and strengthen the research that makes them possible. This research is essential for those still urgently needed to confront emerging diseases and persistent infectious threats for which humanity remains unprotected. Now more than ever, science must remain central to our societies and continue to guide collective decision-making. https://lnkd.in/eUXACmaW #Vaccines #PublicHealth #Science #NIH #GlobalHealth #VaccineResearch

🚨 An HIV vaccine just passed a major clinical trial in humans! Over 80% of participants developed antibodies. In a major step forward in the search for an HIV vaccine, researchers have shown that an mRNA-based vaccine can successfully trigger the immune system to produce potent antibodies against HIV in humans. In a phase 1 trial, 80% of participants who received a version of the vaccine with a membrane-bound HIV envelope protein developed “tier 2” neutralizing antibodies—considered a significant benchmark in HIV vaccine development. These vaccines are modeled after the mRNA technology used in COVID-19 shots but are designed to display the virus’s surface proteins in a more realistic way, potentially guiding the immune system to attack the right viral targets. The study also found that this approach trained the body to make memory B cells and helper T cells, setting the stage for longer-lasting immunity. However, the study revealed an unexpected side effect: 6.5% of participants developed chronic hives, prompting long-term follow-up. Despite this, the results are promising enough to push this new vaccine platform into further trials aimed at generating broader protection. Unlike previous attempts that mostly failed to produce protective antibodies, this strategy targets hard-to-reach regions of the virus that are more likely to block infection. The findings could speed up HIV vaccine development, which has long struggled due to the virus’s high mutation rate and elusive nature. Researchers say the mRNA platform's speed and flexibility may finally offer a viable way forward in the decades-long effort to end the HIV epidemic. Parks, K. R., Moodie, Z., Allen, M. A., Yen, C., Furch, B. D., MacPhee, K. J., et al. (2025). Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Science Translational Medicine, 17(809).

Immune-boosting bacterial platform could aid nasal vaccines Outer membrane vesicles (OMVs) are non-living spherical #nanostructures that derive from the cell envelope of Gram-negative #bacteria. OMVs are important in bacterial #pathogenesis, cell-to-cell communication, horizontal #gene transfer, quorum sensing, and in maintaining bacterial fitness. These structures can be modified to express #antigens of interest using glycoengineering and genetic or chemical modification. The resulting #OMVs can be used to immunize individuals against the expressed homo- or heterologous antigens. Additionally, cargo can be loaded into OMVs and they could be used as a #drugdelivery system. OMVs are inherently #immunogenic due to proteins and glycans found on Gram negative bacterial outer #membranes. OMVs—non-infectious particles naturally released by some bacteria that are known to boost immunity—can enhance intranasal vaccines, strengthening levels of #protection at the point of #pathogen entry so those #vaccinated not only avoid getting sick but also avoid passing on the #infection to others. Abera Bioscience AB’s preclinical studies have shown their OMV-based platform triggers strong #immune responses against various bacterial and viral pathogens, inducing #mucosal immunity. Bacterial OMVs is being investigated for boosting mucosal immunity—which is believed could be key to stopping the onward transmission of several #viruses. Abera Bioscience researchers are modifying OMVs, developed on their proprietary vaccine platform, BERA, with antigens produced by cell-free-production methods, resulting in new immune-boosted nasal #vaccine sprays and powders. OMVs can be stockpiled and, in the event of a new pathogen threat, could be quickly coupled with different antigens to accelerate the #development of new vaccines. The plug-and-play #innovation also supports accessible pricing, facilitates #technology transfer, and has a favourable thermostability profile, all of which are beneficial qualities for LMICs. References: [1] https://lnkd.in/ghi38Bjt; [2] https://lnkd.in/gEtYjVB9 [3] https://lnkd.in/gHwaWbEV; [4] https://lnkd.in/gKsBXTg5 [5] https://lnkd.in/g-4xRS92; [6] https://lnkd.in/gKmJQUyY

For years as a physician, I saw the devastating toll of tuberculosis firsthand. The disability, the suffering, the lives cut short. Later, in government, I saw how it impacted communities and economies. Today, on #WorldTBDay, the message "Yes! We can End TB!" is a welcome note of optimism. With new vaccines for adolescents and adults in the final stages of clinical trials, we have the possibility of saving millions of lives and generating US$ 400 billion in economic benefits by 2050. At Gavi, the Vaccine Alliance, we have a mandate to ensure that these vaccines, once licensed and recommended, reach those that need them most. This is why we are working at pace to estimate future demand, build a roadmap for future supply and to generate data to help them reach the broadest population group possible. Partnership will be essential. We are intensifying our collaboration with the The Global Fund and World Health Organization, and look forward to working in close alignment with Africa CDC, the African Development Bank Group, the Gates Foundation and other leading stakeholders. Read my full perspective here. #WorldTBDay #GlobalHealth #VaccinesWork #EndTB

What if the next vaccine was designed before the outbreak began? Last time, we saw a “vaccine in a ball you could carry in your backpack.” That was about storage and portability. Here’s part two of the story: What if vaccines could be designed in weeks, not years? The Problem Today mRNA vaccines are powerful but fragile. To protect them, we wrap RNA inside tiny fat bubbles called lipid nanoparticles (LNPs). Here’s the bottleneck: there are thousands of possible bubble recipes. Each behaves differently in the body. Testing them one by one is slow, expensive, and unpredictable. The Breakthrough MIT researchers built an AI model trained on thousands of past LNP experiments. It learned the underlying patterns: which chemical structures, charges, and sizes made RNA delivery successful. Now, instead of trial-and-error, the AI can predict which new formulations will work best even with entirely new materials. And it’s not just theory: results published in Nature Nanotechnology showed these AI-designed particles worked in both lab cells and live models. Why This Matters Speed → Vaccine design shrinks from months to weeks. Precision → Tailored therapies for specific tissues, viruses, and even chronic diseases. Scale → Less wasted effort, lower costs, more access worldwide. The Bigger Picture If part one (the backpack nanoball) solved storage, part two (AI-driven design) solves speed. Together, they point to a future where vaccines and RNA therapies aren’t just reactive, they’re proactive. Suchitaa Paatil Sanju S Anju Goel Ajay Nandgaonkar Amit Saxena Taruna Anand #AI #HealthcareInnovation #Vaccines #RNA #mRNA #Biotech #FutureOfHealth #ArtificialIntelligence #DrugDiscovery #Innovation

In 2010, a historic collaboration—led by African governments, World Health Organization, PATH, and the Serum Institute of India Pvt. Ltd.—resulted in MenAfriVac, the first vaccine developed specifically to meet the needs of the African meningitis belt. Priced at less than $0.50 per dose, it targeted meningitis A, which caused 80% of regional outbreaks. The impact was transformative: over 360 million people vaccinated in just 10 years, a 99% drop in meningitis A, and more than one million lives saved. This success reflects the leadership of African governments, the dedication of local health workers, and the power of transformative global partnerships. My colleague Greg Widmyer highlights how this story exemplifies what Gavi, the Vaccine Alliance has achieved over 25 years—helping halve global childhood deaths and supporting vaccine production in many low- and middle-income countries. Today, 19 former Gavi-supported countries are financing their own programs and even contributing as donors. Sustained global solidarity is essential to ensure every child, everywhere, can access vaccines that protect their health and future. 📖 Read more: https://lnkd.in/eYh2GvkE

A simple trick to improve vaccine efficacy. Vaccine design often revolves around the design of either antigen or adjuvant. However, in our latest paper led by Morgan Janes, PhD, we show that a simple addition of a polyphenol to the vaccine formulation increases its persistence at the injection site, and it subsequently increases its exposure to the immune microenvironment, a strategy we call a TAPER vaccine. The result is a significant improvement in the antibody titers against the antigen. TAPER vaccine durably improved humoral response against the receptor-binding domain (RBD) of SARS-CoV-2 while concomitantly enhancing the antigen-specific T cell response. https://lnkd.in/eTiPpWEy Owing to simplicity and ultra-low cost, TAPER vaccine offers a potential tool to improve vaccination outcomes at a larger scale. Alex Gottlieb Charles Park Shrinivas Acharya Griff Bibbey #vaccination #immunization #infectious_disease

Researchers describe a nasally delivered “universal vaccine” strategy that, in mice, provided broad protection against multiple respiratory threats for at least three months. The approach is positioned as a potential seasonal, pre-winter intervention that could offer a first line of defense not only against well-known viruses such as #SARSCoV2 (which causes #COVID19) and #influenza, but also against a range of respiratory pathogens more generally - and possibly help blunt impacts from future #pandemics IF it proves safe and effective in humans. ▪️ The work is led by Prof Pulendran Bali, an immunologist at Stanford University. Pulendran’s group builds on earlier insights from studying the Bacillus Calmette–Guérin (#BCG) #vaccine, which can provide temporary, broad, non-specific protection by stimulating the innate #immunesystem. Unlike conventional vaccines that primarily train the adaptive immune system (B cells and T cells) to recognize specific #pathogen proteins, this new strategy aims to “supercharge” innate defenses also enhancing the ability of respiratory epithelial cells (a frequent target of respiratory pathogens) to resist infection. ▪️The vaccine described uses three components. Two are drugs designed to stimulate receptor proteins that activate innate immune cells such as lung macrophages. The third component engages a subset of #Tcells in the adaptive immune system, whose role is to keep sending sustaining signals so the innate immune system remains in an activated, protective state. The formulation includes an immunogenic protein from chicken eggs; when that component was omitted in experiments, the protective immunity declined quickly. ▪️After four nasal doses, mice showed immunity not only to SARS-CoV-2 and other coronaviruses, but also to bacteria that cause certain respiratory infections. A notable additional effect was suppression of hypersensitivity pathways involved in allergy: the activated immune pathways reduced responses to house dust mites, helping to prevent allergic asthma in the mouse model. ▪️Mechanistic analyses suggest what Pulendran calls a “two-bulwark” system: an initial mucosal barrier reduces pathogen entry into the lungs, and a second layer rapidly mobilizes the pathogen-specific immune response to eliminate any invaders that get through. 🗃️ See comments section for reference.

Revolutionizing mRNA vaccine delivery with piezoelectric electroporation: when the need of LNPs is simply not there. In a new study (just published as a pre-print), researchers have introduced Piezopen, a novel device for enhancing "naked" RNA vaccine delivery. Here's what you should know about this innovative approach: 1) Cost-effective and simple - Piezopen is an inexpensive (less than $1), battery-free, handheld device utilizing piezoelectric electroporation with microneedle electrodes to deliver mRNA directly into cells without needing LNPs. 2) Comparable efficacy to LNPs - The study demonstrates that Piezopen can deliver naked mRNA, self-amplifying RNA (saRNA), and circular RNA (circRNA) with gene expression and immune responses akin to those achieved by state-of-the-art LNPs. This includes robust responses against SARS-CoV-2 mRNA with minimal reactogenicity, even at low doses. 3) Enhanced vaccine durability - Piezopen's method not only matches the immunogenicity of LNPs but does so with improved durability. Gene expression persisted significantly longer, suggesting potential for enhanced vaccine longevity and effectiveness. 4) Translatability across species - The technology has been validated in both rodents and ex vivo human skin, showing promising results for translating this approach into clinical settings. This cross-species efficacy is crucial for moving from preclinical to human trials. 5) Reducing systemic inflammation - Unlike LNPs, which can cause significant inflammation, Piezopen's localized delivery to the epidermis minimizes systemic reactogenicity, offering a safer alternative for RNA vaccine administration. This advancement challenges the current paradigm of RNA vaccine delivery, proposing a pathway for more accessible, effective, and less inflammatory mRNA vaccines. By potentially reducing the need for complex LNPs, Piezopen could democratize mRNA vaccine technology, enhancing global vaccination efforts. Learn more about the article here: https://lnkd.in/e4e3h9P4 #mRNAVaccines #VaccineTechnology #InnovationInHealthcare #RNATherapeutics #Electroporation